Loperamide

Phase 2

ASTRAZENECA PLC (AZNCF)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Apr '27

AZNCFPhase 2$290.6B

Loperamide Phase 2 Est. Readout

Loperamide• Metastatic HR+/HER2- Breast Cancer108

Apr 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Metastatic HR+/HER2- Breast Cancer

View Full Landscape

Drug Information

Target Indication

Metastatic HR+/HER2- Breast Cancer

Clinical Trial

NCT07426822

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Biotechnology•North America•NASDAQ

Related Pipeline

Administration of quetiapine XRPhase 3

Schizophrenia

quetiapine fumarate or valproatePhase 3

Bipolar Disorder

Ticagrelor mashed pillsPhase 3

Acute Coronary Syndrome

Alendronate sodiumPhase 3

Breast Cancer

fluticasonePhase 3

Asthma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts